These so-called hot-spot mutations account for 30% of all p53 mutations in human cancers (6), with higher penetrance in ovarian serous carcinoma (96%), small cell lung cancer (85%), and pancreatic ductal adenocarcinoma (PDAC, 75%) (2,6,7). This evidence concerns the gene TP53 and cancer.